LQDA Liquidia Technologies, Inc.
Price Chart
Executive Summary
Liquidia Technologies reported strong full-year 2025 financial results driven by $148.3 million in net product sales of YUTREPIA®, its inhaled treprostinil therapy for PAH and PH-ILD, launched in June 2025. The company achieved its second consecutive profitable quarter with $14.6 million in net income in Q4 and ended the year with $190.7 million in cash, up from $176.5 million in Q3. Despite a reduced net loss of $68.9 million for the full year (down from $128.3 million in 2024), the commercial momentum and self-funded growth plans signal strong market adoption.
Key Financial Metrics
Actionable Insight
The rapid uptake of YUTREPIA and transition to profitability suggest strong commercial viability. Traders should monitor prescription growth, litigation developments with United Therapeutics, and progress on L606 pivotal trials as key catalysts. The ability to fund growth from operations reduces near-term dilution risk.
Key Facts
- YUTREPIA® generated $148.3 million in net product sales in 2025, with $90.1 million in Q4 alone
- Company achieved second consecutive profitable quarter with $14.6 million net income in Q4 2025
- Cash and cash equivalents increased to $190.7 million as of December 31, 2025, up $33.2 million from Q3
- Net loss for 2025 was $68.9 million, a significant improvement from $128.3 million in 2024
- More than 3,600 unique prescriptions and 2,900 patients treated since launch in June 2025
- Selling, general and administrative expenses rose 93% to $157.2 million, primarily due to YUTREPIA commercialization
Financial Impact
YUTREPIA generated $148.3 million in revenue in its first full year post-launch, representing a new core revenue stream. The drug drove profitability in the second half of 2025, with positive non-GAAP EBITDA of $27.3 million in Q4.
Risk Factors
- Ongoing patent litigation with United Therapeutics could result in an injunction blocking YUTREPIA sales
- High SG&A spend ($157.2M) raises questions about long-term margin sustainability
- Service revenue declined $4.0 million due to lower Treprostinil Injection sales, indicating potential erosion in legacy business
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249963 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
2d ago
|
Institutional Cluster
| $65.50 awaiting T+1 | awaiting T+1 | — | $71.23 (+8.75%) |
|
Jun 10, 2026
2d ago
|
144
| $65.21 awaiting T+1 | awaiting T+1 | — | $71.23 (−9.23%) |
|
Jun 8, 2026
4d ago
|
Insider Cluster
| $63.94 awaiting T+1 | awaiting T+1 | — | $71.23 (+11.40%) |
|
Jun 8, 2026
4d ago
|
CLUSTER / 8-K
| $63.94 awaiting T+1 | awaiting T+1 | — | $71.23 (+11.40%) |
|
Jun 4, 2026
8d ago
|
144
| $62.76 awaiting T+1 | awaiting T+1 | — | $71.23 (−13.50%) |
|
Jun 4, 2026
8d ago
|
144
| $62.76 awaiting T+1 | awaiting T+1 | — | $71.23 (−13.50%) |
|
Jun 3, 2026
9d ago
|
Insider Cluster
| $62.54 $61.85 | ▼ −1.10% | ▲ +1.50% | $71.23 (+13.90%) |
|
Jun 1, 2026
12d ago
|
144
| $58.75 $55.11 | ▼ −6.20% | ▼ −6.34% | $71.23 (+21.24%) |
|
May 26, 2026
17d ago
|
Insider Cluster
| $62.03 $62.03 | · 0.00% | ▼ −0.55% | $71.23 (+14.83%) |
|
May 21, 2026
23d ago
|
Insider Cluster
| $61.97 $60.98 | ▼ −1.60% | ▼ −2.04% | $71.23 (+14.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access